| 1 |
Mitochondria-targeted antioxidants protect against mechanical ventilation-induced diaphragm weakness*
Scott K. Powers, Matthew B. Hudson, W. Bradley Nelson et al. · Critical Care Medicine
Open access |
Apr 2011 |
253 |
| 2 |
MAP3K11/GDF15 axis is a critical driver of cancer cachexia
Lorena R. Lerner, Julie Tao, Qing H. Liu et al. · Journal of Cachexia Sarcopenia and Muscle
Open access |
29 Oct 2015 |
188 |
| 3 |
The NeurostationTM—A highly accurate, minimally invasive solution to frameless stereotactic neurosurgery
Kurt R. Smith, Kevin J. Frank, Richard D. Bucholz · Computerized Medical Imaging and Graphics
|
Jul 1994 |
182 |
| 4 |
Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy
Amel Karaa, Richard Haas, Amy C. Goldstein et al. · Neurology
Open access |
2 Mar 2018 |
155 |
| 5 |
A phase 2/3 randomized clinical trial followed by an open-label extension to evaluate the effectiveness of elamipretide in Barth syndrome, a genetic disorder of mitochondrial cardiolipin metabolism
William Reid Thompson, Brittany Hornby, Ryan Manuel et al. · Genetics in Medicine
Open access |
19 Oct 2020 |
136 |
| 6 |
Frameless stereotactic ultrasonography: Method and applications
Jason W. Trobaugh, William D. Richard, Kurt R. Smith et al. · Computerized Medical Imaging and Graphics
|
Jul 1994 |
131 |
| 7 |
Effects of Elamipretide on Left Ventricular Function in Patients With Heart Failure With Reduced Ejection Fraction: The PROGRESS-HF Phase 2 Trial
Javed Butler, Muhammad Shahzeb Khan, Stefan D. Anker et al. · Journal of Cardiac Failure
Open access |
14 Feb 2020 |
111 |
| 8 |
Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy
Amel Karaa et al. · Neurology
Open access |
2 Jun 2023 |
81 |
| 9 |
Design and engineering of deimmunized biotherapeutics
Karl E. Griswold, Chris Bailey‐Kellogg · Current Opinion in Structural Biology
ReviewOpen access |
18 Jun 2016 |
54 |
| 10 |
The Case for the Use of Patient and Caregiver Perception of Change Assessments in Rare Disease Clinical Trials: A Methodologic Overview
Marielle Goyette Contesse, James E. Valentine, Tracy Wall et al. · Advances in Therapy
Open access |
16 Mar 2019 |
43 |
| 11 |
Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER
William Reid Thompson, Ryan Manuel, Anthony Abbruscato et al. · Genetics in Medicine
Open access |
8 Apr 2024 |
41 |
| 12 |
Computationally optimized deimmunization libraries yield highly mutated enzymes with low immunogenicity and enhanced activity
Regina S. Salvat, Deeptak Verma, Andrew Scott Parker et al. · Proceedings of the National Academy of Sciences
Open access |
12 Jun 2017 |
40 |
| 13 |
ReCLAIM-2: A Randomized Phase II Clinical Trial Evaluating Elamipretide in Age-related Macular Degeneration, Geographic Atrophy Growth, Visual Function, and Ellipsoid Zone Preservation
Justis P. Ehlers et al. · Ophthalmology Science
Open access |
9 Oct 2024 |
35 |
| 14 |
Exploring the Acceleration Limits of Deep Learning Variational Network–based Two-dimensional Brain MRI
Alireza Radmanesh, Matthew J. Muckley, Tullie Murrell et al. · Radiology Artificial Intelligence
Open access |
Nov 2022 |
32 |
| 15 |
SBT-272 improves TDP-43 pathology in ALS upper motor neurons by modulating mitochondrial integrity, motility, and function
Mukesh Gautam, Barış Genç, Benjamin Helmold et al. · Neurobiology of Disease
Open access |
27 Jan 2023 |
29 |
| 16 |
Globally deimmunized lysostaphin evades human immune surveillance and enables highly efficacious repeat dosing
Hongliang Zhao, Seth A. Brooks, Susan K. Eszterhas et al. · Science Advances
Open access |
2 Sep 2020 |
29 |
| 17 |
Intraoperative localization using a three-dimensional optical digitizer
Richard D. Bucholz, Kurt R. Smith, Jaimie M. Henderson et al. · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE
Conference paper |
17 Sep 1993 |
27 |
| 18 |
A retrospective analysis of health care utilization for patients with mitochondrial disease in the United States: 2008–2015
Bruce Cohen, Cristy Balcells, Brian Hotchkiss et al. · Orphanet Journal of Rare Diseases
Open access |
22 Nov 2018 |
25 |
| 19 |
Patient Voice in Rare Disease Drug Development and Endpoints
Linda S. Deal, Jonathan C. Goldsmith, Susan A. Martin et al. · Therapeutic Innovation & Regulatory Science
|
4 Nov 2016 |
25 |
| 20 |
Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome
Brittany Hornby, William Reid Thompson, Mohammed Almuqbil et al. · Orphanet Journal of Rare Diseases
Open access |
2 Sep 2022 |
24 |
| 21 |
The mitochondria-targeting peptide elamipretide diminishes circulating HtrA2 in ST-segment elevation myocardial infarction
Marcus Hortmann, Samuel D. Robinson, M. Mohr et al. · European Heart Journal Acute Cardiovascular Care
Open access |
23 May 2017 |
24 |
| 22 |
Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial
Amel Karaa et al. · Orphanet Journal of Rare Diseases
Open access |
21 Nov 2024 |
14 |
| 23 |
Deimmunized Lysostaphin Synergizes with Small-Molecule Chemotherapies and Resensitizes Methicillin-Resistant Staphylococcus aureus to β-Lactam Antibiotics
Yongliang Fang, Jack R. Kirsch, Liang Li et al. · Antimicrobial Agents and Chemotherapy
Open access |
14 Dec 2020 |
13 |
| 24 |
Safety, pharmacokinetics and pharmacodynamics of SBT‐020 in patients with early stage Huntington's disease, a 2‐part study
Marcus P.J. van Diemen, Ellen P. Hart, Anthony Abbruscato et al. · British Journal of Clinical Pharmacology
Open access |
16 Nov 2020 |
13 |
| 25 |
The effects of a mitochondrial targeted peptide (elamipretide/SS31) on BAX recruitment and activation during apoptosis
Joshua A. Grosser, Rachel L. Fehrman, Dennis Keefe et al. · BMC Research Notes
Open access |
22 May 2021 |
10 |
| 26 |
Relation of Left Ventricular Mass and Infarct Size in Anterior Wall ST-Segment Elevation Acute Myocardial Infarction (from the EMBRACE STEMI Clinical Trial)
Yazan Daaboul, Serge Korjian, W. Douglas Weaver et al. · The American Journal of Cardiology
|
18 Jun 2016 |
10 |
| 27 |
Psychometric performance of the Primary Mitochondrial Myopathy Symptom Assessment (PMMSA) in a randomized, double-blind, placebo-controlled crossover study in subjects with mitochondrial disease
Chad J. Gwaltney, Jonathan Stokes, Anthony Aiudi et al. · Journal of Patient-Reported Outcomes
Open access |
23 Dec 2022 |
9 |
| 28 |
Development and content validity of the Barth Syndrome Symptom Assessment (BTHS-SA) for adolescents and adults
Chad J. Gwaltney, Jonathan Stokes, Anthony Aiudi et al. · Orphanet Journal of Rare Diseases
Open access |
9 Jun 2021 |
8 |
| 29 |
Patient Guidance and Remote Care With AI and AR
Prashant Singh, Gaurav Prasad, Harmohinder S. Athwal et al. · Advances in healthcare information systems and administration book series
Book chapter |
16 Aug 2024 |
4 |
| 30 |
Cellular Context Dictates the Suppression or Augmentation of Triple-Negative Mammary Tumor Metastasis by NLRX1
Margaret A. Nagai-Singer, Mackenzie K. Woolls, Katerina Leedy et al. · The Journal of Immunology
Open access |
Nov 2023 |
4 |
| 31 |
Metabolomic biomarkers from patients with Barth syndrome treated with elamipretide: insights from the TAZPOWER study
Peter J. Oates, David Alexander Brown, Hilary J. Vernon et al. · medRxiv
PreprintOpen access |
23 Nov 2020 |
4 |
| 32 |
Development of a Patient-Reported Outcome Questionnaire to Evaluate Primary Mitochondrial Myopathy Symptoms: The Primary Mitochondrial Myopathy Symptom Assessment
Chad J. Gwaltney, Jonathan Stokes, Anthony Aiudi et al. · Journal of Clinical Neuromuscular Disease
|
17 Nov 2020 |
4 |
| 33 |
Frameless image-guided surgery utilizing an optical digitizer
Richard D. Bucholz, Kurt R. Smith, Lee L. McDurmont et al. · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE
Conference paper |
26 May 1994 |
4 |
| 34 |
Extracellular Thimet Oligopeptidase is Released with Extracellular Vesicles from Human Prostate Cancer Cells
Yu Liu, Lisa A. Bruce, Adele J. Wolfson · bioRxiv (Cold Spring Harbor Laboratory)
PreprintOpen access |
10 May 2020 |
3 |
| 35 |
ЕФЕКТИВНІСТЬ ВИКОРИСТАННЯ КВАНТОВИХ КОМП’ЮТЕРІВ У РОЗВ’ЯЗАННІ СКЛАДНИХ ЗАВДАНЬ
Oleg Bondarchuk, Serhii Zybin, Svitlana Vasylyuk-Zaitseva · INFORMATION TECHNOLOGY AND SOCIETY
Open access |
30 Dec 2024 |
1 |
| 36 |
Genetic subgroup learnings from MMPOWER-3 trial: Elamipretide improved six-minute walk test in individuals with mtDNA replisome disorders
Amel Karaa, Michelangelo Mancuso, Bruce M. Cohen et al. · Biochimica et Biophysica Acta (BBA) - Bioenergetics
Open access |
20 Aug 2022 |
1 |
| 37 |
The mitochondria-targeting peptide Elamipretide preserves mitochondrial function and protects the heart against ischemia-reperfusion damage
Janis Kuka, Marina Makrecka‐Kuka, Edijs Vavers et al. · Proceedings for Annual Meeting of The Japanese Pharmacological Society
Open access |
2018 |
1 |
| 38 |
Breaking and fixing content-based filtering
Mayank Dhiman, Markus Jakobsson, Ting-Fang Yen
Conference paper |
Apr 2017 |
1 |
| 39 |
Bulk RNAseq of cardiac myosin-specific CD4 and CD8 T cells reveals distinct transcriptomic profiles between myocarditis-resistant and susceptible mice 2256473
Shraddha Singh, Meghna Sur, Kiruthiga Mone et al. · The Journal of Immunology
|
28 Jul 2026 |
0 |
| 40 |
Publicly Available Clinical Trial Safety Data: Review and a Call for Standardization and Improved Reporting Practices
Barbara A. Hendrickson, Cynthia McShea, Tarek A. Hammad et al. · Pharmaceutical Medicine
Open access |
16 Dec 2025 |
0 |
| 41 |
Unpaired Electrons-Empowered Bridge-Site Lattice Oxygen for Efficient CO 2 -to-CH 4 Conversion via a CO 2 /H 2 Fuel Cell
Yan Liu, Yan Liu, Ji‐Xiang Hu et al. · Nano Letters
|
13 Dec 2025 |
0 |
| 42 |
Bulk RNAseq Analysis of Cardiac Myosin-Specific CD4+ and CD8+ T Cells Reveals Distinct Transcriptomic Profiles Between Myocarditis-Resistant and Susceptible Mice
Shraddha Singh, Meghna Sur, Kiruthiga Mone et al. · Biomedicines
Open access |
6 Nov 2025 |
0 |
| 43 |
Initial Psychometric Evaluation of the Barth Syndrome Symptom Assessment (BTHS-SA) for Adolescents and Adults in a Phase 2 Clinical Study
Chad J. Gwaltney, Alan L. Shields, Emily Love et al. · Orphanet Journal of Rare Diseases
Open access |
25 Apr 2025 |
0 |
| 44 |
Cellular protection and preservation of bioenergetics by the novel compound SBT-589 in a fibroblast model of Leigh syndrome
Laura E. Kropp, Alyssa Handler, Hatim A. Zariwala et al. · Biochimica et Biophysica Acta (BBA) - Bioenergetics
Open access |
26 Aug 2024 |
0 |
| 45 |
Interventions with Potential to Mitigate Injection Site Reactions Following Subcutaneous Elamipretide Administration: A Phase 1, Crossover Study
Sandrin C. Bergheanu, Benjamin D. McNeil, Alana Sullivan et al.
PreprintOpen access |
12 Jul 2023 |
0 |
| 46 |
Interventions with Potential to Mitigate Injection Site Reactions Following Subcutaneous Elamipretide Administration: A Phase 1, Crossover Study
Alana Sullivan, Sandrin C. Bergheanu, Laura E. Kropp et al.
PreprintOpen access |
6 Apr 2023 |
0 |
| 47 |
SBT-272 improves TDP-43 pathology in the ALS motor cortex by modulating mitochondrial integrity, motility, and function
Mukesh Gautam, Barış Genç, Benjamin Helmold et al. · bioRxiv (Cold Spring Harbor Laboratory)
PreprintOpen access |
7 Oct 2022 |
0 |
| 48 |
Preservation of bioenergetics and inhibition of ferroptosis with the novel compound SBT-588 in Friedreich’s ataxia cell models
Laura E. Kropp, Hatim A. Zariwala, Yunmi Park et al. · Biochimica et Biophysica Acta (BBA) - Bioenergetics
Open access |
20 Aug 2022 |
0 |
| 49 |
Elamipretide Prevents the Natural History Progression of Cardiomyopathy-Related Disease Symptomatology in Patients with Barth Syndrome: A Tazpower Analysis
William Reid Thompson, Ryan Manuel, John J. Jones et al. · Journal of Cardiac Failure
|
30 Sep 2020 |
0 |